Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3KN7V)

Drug Name
Bifonazole Drug Info
Synonyms
Amycor; Azolmen; Bifokey; Bifomyk; Bifon; Bifonazol; Bifonazolum; Moldina; Mycospor; Trifonazole; Bayer brand of bifonazole; Bioglan brand of bifonazole; Canesten Extra Bifonazol; Canesten brand of bifonazole; Dermapharm brand of bifonazole; Inkeysa brand of bifonazole; Juventus brand of bifonazole; Merck Lipha Sante brand of bifonazole; Bay H-4502; Bifonazol [INN-Spanish]; Bifonazolum [INN-Latin]; Canespor (TN); Mycospor (TN); Bay-h-4502; Bifonazole (JP15/USAN/INN); Bifonazole [USAN:BAN:INN:JAN]; (+-)-1-([1,1'-Biphenyl]-4-ylphenylmethyl)-1H-imidazole; (+-)-1-(p,alpha-Diphenylbenzyl)imidazole; 1-((4-Biphenylyl)phenylmethyl)-1H-imidazole; 1-(alpha-(4-Biphenylyl)benzyl)imidazole; 1-(p,alpha-Diphenylbenzyl)imidazole; 1-[4,alpha-Diphenylbenzyl]-imidazole; 1-[biphenyl-4-yl(phenyl)methyl]-1H-imidazole; 1-[phenyl-(4-phenylphenyl)methyl]imidazole
Therapeutic ClassAntifungal Agents
Cross-matching ID
PubChem CID
2378
ChEBI ID
CHEMBL277535
CAS Number
CAS 60628-96-8
TTD Drug ID
D0AA2D

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mucin type O-glycan biosynthesis 1.75 2.85e-1 20/36 (55.56%) GALNT12;GALNT7;GCNT3;...
VEGF signaling pathway 1.73 1.74e-1 50/59 (84.75%) PPP3CA;PLA2G4A;PIK3CA;...
beta-Alanine metabolism 1.73 1.20e-1 25/30 (83.33%) ALDH3A2;ALDH2;ALDH3A1;...
Amino sugar and nucleotide sugar metabolism 1.71 1.08e-1 38/48 (79.17%) UAP1;UGP2;AMDHD2;...
Primary immunodeficiency 1.65 1.84e-1 33/38 (86.84%) CD40;CD79A;BLNK;...
Intestinal immune network for IgA production 1.58 2.77e-1 38/48 (79.17%) CD40;IL6;HLA-DOB;...
Steroid biosynthesis 1.57 2.72e-1 19/20 (95%) SQLE;TM7SF2;LIPA;...
Synthesis and degradation of ketone bodies 1.53 3.11e-1 9/10 (90%) HMGCS1;BDH1
N-Glycan biosynthesis 1.50 3.90e-1 38/50 (76%) ST6GAL1;MAN1A2;MGAT2;...
alpha-Linolenic acid metabolism 1.49 3.69e-1 17/25 (68%) PLA2G4A;PLAAT3;PLA2G5;...
Fatty acid degradation 1.47 3.97e-1 40/43 (93.02%) ACSL3;ALDH3A2;ADH1B;...
Histidine metabolism 1.46 4.05e-1 16/22 (72.73%) ALDH3A2;MAOA;ALDH2;...
Aminoacyl-tRNA biosynthesis 1.46 3.74e-1 15/66 (22.73%) CARS2;NARS2;QRSL1;...
Other types of O-glycan biosynthesis 1.45 3.80e-1 29/47 (61.7%) GALNT12;ST6GAL1;GALNT7;...
Glutamatergic synapse 1.43 4.05e-1 97/114 (85.09%) PPP3CA;PLA2G4A;PRKACB;...
Hematopoietic cell lineage 1.42 4.02e-1 90/99 (90.91%) MS4A1;IL6;HLA-DOB;...
Ether lipid metabolism 1.37 4.83e-1 32/49 (65.31%) PLA2G4A;ENPP2;LPCAT4;...
Ovarian steroidogenesis 1.37 4.68e-1 41/51 (80.39%) CYP1B1;PLA2G4A;PRKACB;...
D-Glutamine and D-glutamate metabolism 1.26 4.84e-1 5/5 (100%) GLS;GLUD1
Regulation of lipolysis in adipocytes 1.26 4.77e-1 52/55 (94.55%) FABP4;PRKACB;PIK3CA;...
Purine metabolism 1.26 4.69e-1 102/129 (79.07%) PAPSS1;NME3;ADCY1;...
Peroxisome 1.26 4.65e-1 72/82 (87.8%) ACSL3;HSD17B4;PEX6;...
Glycerolipid metabolism 1.24 4.80e-1 44/61 (72.13%) ALDH3A2;ALDH2;AKR1B1;...
Salivary secretion 1.24 4.72e-1 76/93 (81.72%) DMBT1;PRKACB;ITPR1;...
Asthma 1.24 4.63e-1 25/31 (80.65%) CD40;HLA-DOB;HLA-DMB
Platelet activation 1.24 4.60e-1 106/124 (85.48%) PLA2G4A;PRKACB;ITPR1;...
C-type lectin receptor signaling pathway 1.20 4.82e-1 93/104 (89.42%) PPP3CA;CCL17;IL6;...
Type II diabetes mellitus 1.20 4.78e-1 42/46 (91.3%) SOCS1;PIK3CA;IRS2;...
ECM-receptor interaction 1.20 4.75e-1 80/88 (90.91%) SPP1;SDC1;COMP;...
Ubiquitin mediated proteolysis 1.18 4.81e-1 87/140 (62.14%) SOCS1;CDC20;KLHL9;...
Retinol metabolism -1.12 6.25e-1 41/68 (60.29%) ADH6;UGT2B4;UGT2A3;...
Glycolysis / Gluconeogenesis -1.13 6.23e-1 56/67 (83.58%) PGK1;ENO1;TPI1;...
Glyoxylate and dicarboxylate metabolism -1.14 6.17e-1 23/30 (76.67%) GLUL;DLD;GLDC
Thyroid hormone signaling pathway -1.14 6.13e-1 112/121 (92.56%) MED1;MDM2;ATP1B2;...
Coronavirus disease -1.15 6.00e-1 215/232 (92.67%) SELP;RPL13A;RPL24;...
Viral carcinogenesis -1.15 6.00e-1 149/203 (73.4%) CDKN1A;PIK3R1;NFKB2;...
Prostate cancer -1.15 6.10e-1 93/97 (95.88%) NFKBIA;CCNE1;ETV5;...
Pertussis -1.16 5.94e-1 64/76 (84.21%) C1QB;CD14;CXCL8;...
Amyotrophic lateral sclerosis -1.16 5.98e-1 267/364 (73.35%) NUP58;PINK1;PSMD7;...
Hepatitis C -1.16 6.10e-1 139/157 (88.54%) IFNA8;JAK1;PIK3CD;...
Melanoma -1.16 6.23e-1 68/72 (94.44%) MDM2;MAP2K2;GADD45G;...
Measles -1.17 6.16e-1 133/139 (95.68%) IFIH1;IFNA21;FOS;...
Aldosterone-regulated sodium reabsorption -1.19 6.18e-1 34/37 (91.89%) ATP1B2;SGK1;SFN;...
Human cytomegalovirus infection -1.19 6.22e-1 201/225 (89.33%) GNG12;PPP3R1;MAPK14;...
Hippo signaling pathway -1.19 6.21e-1 120/186 (64.52%) FZD10;SMAD7;TGFBR1;...
Natural killer cell mediated cytotoxicity -1.20 6.23e-1 99/131 (75.57%) SH2D1A;MAP2K2;SOS1;...
Glioma -1.23 6.03e-1 67/75 (89.33%) MDM2;MAP2K2;SOS1;...
Steroid hormone biosynthesis -1.23 6.07e-1 43/61 (70.49%) COMT;AKR1C2;AKR1C1;...
Circadian rhythm -1.24 6.05e-1 26/31 (83.87%) SKP1;NPAS2;PRKAA1;...
MicroRNAs in cancer -1.26 6.21e-1 146/310 (47.1%) MAP2K2;SPRY2;ERBB3;...
NOD-like receptor signaling pathway -1.33 5.18e-1 145/181 (80.11%) NLRP3;PLCB1;CYBB;...
Endocytosis -1.34 5.10e-1 198/252 (78.57%) ARRB1;SMURF1;ARF1;...
Chagas disease -1.34 5.32e-1 93/102 (91.18%) PLCB1;TGFBR1;C1QA;...
Legionellosis -1.36 4.93e-1 51/57 (89.47%) RAB1A;ITGB2;ARF1;...
Viral myocarditis -1.36 5.23e-1 53/60 (88.33%) EIF4G2;ICAM1;HLA-DRA;...
Hepatitis B -1.36 5.51e-1 151/162 (93.21%) ATP6AP1;IFIH1;IFNA21;...
Cellular senescence -1.36 5.88e-1 139/156 (89.1%) MDM2;HIPK1;MAP2K2;...
Porphyrin and chlorophyll metabolism -1.61 3.31e-1 23/43 (53.49%) GUSB;ALAS1;CPOX;...
Phagosome -1.64 3.70e-1 118/152 (77.63%) DYNC1LI2;CLEC7A;SEC61G;...
Bladder cancer -1.84 1.03e-1 40/41 (97.56%) MDM2;MAP2K2;RASSF1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H